BPC-157
Body Protection Compound-157 · Pentadecapeptide
Overview
Synthetic peptide derived from gastric juice protein, renowned for tissue repair, inflammation reduction, and GI protection capabilities. BPC-157 promotes blood vessel formation, collagen synthesis, modulates growth factor expression, and protects against tissue damage through localized or systemic delivery.
Promotes blood vessel formation (angiogenesis), collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways.
Accelerated tendon-to-bone healing with improved biomechanical properties; most effective with localized injection.
healing and reduced recovery following crush injuries and surgical procedures with direct tissue targeting.
Promotes blood vessel formation and improves vascularization through localized delivery.
Mechanism
Synthetic peptide derived from gastric juice protein, renowned for tissue repair, inflammation reduction, and GI protection capabilities. BPC-157 promotes blood vessel formation, collagen synthesis, modulates growth factor expression, and protects against tissue damage through localized or systemic delivery.
Promotes blood vessel formation (angiogenesis), collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways.
Accelerated tendon-to-bone healing with improved biomechanical properties; most effective with localized injection.
Research areas
- Synthetic peptide derived from gastric juice protein, renowned for tissue repair, inflammation reduction, and GI protection capabilities. BPC-157 promotes blood vessel formation, collagen synthesis, modulates growth factor expression, and protects against tissue damage through localized or systemic delivery.
- Promotes blood vessel formation (angiogenesis), collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways.
- Accelerated tendon-to-bone healing with improved biomechanical properties; most effective with localized injection.
- healing and reduced recovery following crush injuries and surgical procedures with direct tissue targeting.
- Promotes blood vessel formation and improves vascularization through localized delivery.
Research notes
- Mild injection site redness
- Injection site irritation
- Possible mild digestive adjustment (oral)
- Persistent injection site reactions or infection signs
- Unusual swelling or rash around injection area
References
- pubmed.ncbi.nlm.nih.gov/39325560/
- pubmed.ncbi.nlm.nih.gov/32334036/
- pubmed.ncbi.nlm.nih.gov/40131143/
- pubmed.ncbi.nlm.nih.gov/27847966/
- pubmed.ncbi.nlm.nih.gov/14554208/
- pubmed.ncbi.nlm.nih.gov/32445447/
- pubmed.ncbi.nlm.nih.gov/31266512/
- pubmed.ncbi.nlm.nih.gov/16609979/
Questions
Should I inject BPC-157 near the injury site or take it systemically?
Localized injection near the injury site is most effective for direct tissue targeting and healing. However, BPC-157 has systemic effects, so oral administration (on empty stomach) or distant SubQ injection provides whole-body benefits. For serious tendon/joint injuries, localized injection + oral combination protocol…
Can I use BPC-157 with NSAIDs like ibuprofen?
BPC-157 rescued NSAID-cytotoxicity by stabilizing intestinal permeability and protecting mucosal barrier function in research. This suggests potential synergy—BPC-157 may mitigate NSAID side effects while NSAIDs reduce acute inflammation. However, clinical data on combination timing and dosing doesn't exist.
How long can I use BPC-157 or does it require cycling?
BPC-157 is typically used for 4-12 weeks depending on injury severity. Its short half-life (<30 minutes) and safety profile in preclinical studies suggest longer use is likely safe, but formal long-term human data doesn't exist. Cycling 1-2 weeks on/off may prevent adaptation, though continuous use hasn't shown…
Why must I avoid BPC-157 if I have cancer or am on blood thinners?
BPC-157 promotes angiogenesis (new blood vessel formation), which theoretically could support tumor blood supply. For cancer patients, this creates potential risk despite no direct clinical data. Blood thinners combined with pro-angiogenic effects increase bleeding risk, warranting medical supervision before use.